NVIDIA – 2026-01-13 - Increase Confidence 8/10

NVDA – Increase in Days/Weeks

NVIDIA posted record Q3 2025 revenue of $57.0 billion, driven by 66% YoY growth in Data Center sales. The company’s recent partnership with Eli Lilly to launch an AI-driven drug discovery lab reinforces enterprise adoption of its AI platforms.

Why This Matters

NVIDIA’s financial momentum is accelerating as its AI infrastructure dominance—80% market share—translates into real-world industrial and scientific applications. The Eli Lilly collaboration serves as a high-profile validation of NVIDIA’s agentic AI and Omniverse platforms beyond tech, expanding total addressable market visibility just as Q3 results confirm sustained demand, making near-term downside less likely despite elevated valuation.

Key Insights

• Revenue Growth: $57.0B Q3 2025 revenue, +62% YoY, with Data Center at $51.2B (+66% YoY)
• News Impact: Partnership with Eli Lilly validates AI in biopharma, signaling new vertical expansion
• Risk/Offset: High debt/equity (9.1) and beta (2.314) increase volatility risk if macro conditions shift

Practical Implications

• Bull Case: Continued institutional buying and AI adoption momentum could drive price toward $212 (52-week high) by end of January
• Bear Case: Profit-taking after recent highs or broader tech sell-off could trigger pullback to $170 support
• Confidence: 8/10 – Strong fundamentals and news catalysts outweigh short-term bearish technicals

Prediction: increase

Reference:

• From internal analysis.